We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Patient Consents Sample Clauses

Patient ConsentsParticipant shall conform with the applicable requirements of HIPAA and all other applicable federal, state and local laws, rules and regulations (“Applicable Law”) with respect to the submission and use of Participant Information and Participating Provider Information. In no event shall Participant submit any data to the CPC-HIE System if such data is subject to Applicable Law that would not permit use and disclosure by other Participating Providers and Authorized Users as set forth in this Section 2.2. Specifically, but without limitation of the foregoing, if Participant is subject to a more stringent state or local law with respect to mental health records or other special category of PHI, Participant shall ensure that it either: (a) does not submit such records or information to the CPC-HIE System; or (b) has obtained all necessary consents, permissions or written authorization that comply with Applicable Law (collectively, “Patient Consents”) from the patients whose data will be submitted. It is noted that Patient Consent for use and disclosure and access by other Participating Providers to certain types of PHI is required by the laws of the District of Columbia and the Commonwealths of Maryland and Virginia. IN ALL CASES, IT SHALL BE PARTICIPANT’S OBLIGATION AND DUTY TO VERIFY COMPLIANCE WITH ALL APPLICABLE LAW WITH RESPECT TO THE SUBMISSION AND USE OF ANY PHI SUBMITTED TO THE CPC-HIE SYSTEM. PARTICIPANT AND DCPCA SHALL EACH HAVE A DUTY TO PROMPTLY NOTIFY THE OTHER PARTIES OF ANY ACTUAL OR SUSPECTED LACK OF COMPLIANCE WITH CONSENT REQUIREMENTS WHICH ARE KNOWN OR SHOULD BE KNOWN TO THE PARTY. HOWEVER, IN NO EVENT SHALL DCPCA BE RESPONSIBLE FOR ANY SUCH DETERMINATIONS AND PARTICIPANT SHALL DEFEND, INDEMNIFY AND HOLD DCPCA, OTHER PARTICIPATING PROVIDERS AND THE CPC-HIE HARMLESS FROM ANY CLAIMS, LIABILITIES, COSTS AND/OR EXPENSES (INCLUDING REASONABLE ATTORNEYS’ FEES) RELATING TO ANY FAILURE TO OBTAIN APPROPRIATE PATIENT CONSENTS FROM ANY PATIENT.
Patient ConsentsTo the extent required by law, the party requesting access to patient records shall be required to furnish Provider with an appropriate patient consent form in order to obtain such access.
Patient Consents. The Host shall obtain the proper written consents from volunteer patients for any Procedures to be performed (“Consents”), and shall maintain the Consents on file with the Host Institution for a period of ten (10) years. Host shall make copies of such consents available to ASDS upon request. All such Consents shall confirm the following: A. That the patient has been advised of any reasonably known medical risks associated with any Procedures to be performed, including any increased risks associated with having the Procedures performed; B. That the patient understands and agrees that the Procedures may be: (i) performed in the presence of physician attendees, (ii) recorded in video, audio or any other recording medium (“Recordings”), and (iii) such Recordings may be broadcast, republished, and/or distributed in any form or media for future education of additional physicians; C. That the ASDS is not responsible for the performance or outcome of any Procedures performed; and D. That the patient will be responsible for obtaining any follow-up care that may be required.
Patient Consents. Oxford shall use its Best Efforts on behalf of PA HRM to obtain, in connection with the enrollment and continuing participation of Covered Members in an Oxford Plan or otherwise, such written consents, releases, and authorizations from all Oxford Members as shall be legally sufficient to enable Oxford to obtain such information as necessary for Oxford to perform the services under this Agreement, and to share such information with PA HRM as provided herein. Both parties shall treat such information confidentially consistent with applicable laws and regulations.
Patient Consents. If Customer is a healthcare provider, prior to requesting medication history data for a specific Patient, You will obtain a signed consent from each Patient (a) affirming the Patient’s desire to either opt-in or opt-out of receiving the Services and (b) authorizing You to obtain medication history data about the specific Patient. You must comply with any privacy and patient consent policies of Surescripts related to the delivery of Private Information as Surescripts publishes or amends from time to time.

Related to Patient Consents

  • Cooperation; Consents Prior to the Closing, each party shall cooperate with the other parties to the end that the parties shall (i) in a timely manner make all necessary filings with, and conduct negotiations with, all authorities and other persons the consent or approval of which, or the license or permit from which is required for the consummation of the Acquisition and (ii) provide to each other party such information as the other party may reasonably request in order to enable it to prepare such filings and to conduct such negotiations.

  • Governmental Authorization; Third Party Consents No approval, consent, compliance, exemption, authorization or other action by, or notice to, or filing with, any Governmental Authority or any other Person, and no lapse of a waiting period under any Requirement of Law, is necessary or required in connection with the execution, delivery or performance (including, without limitation, the purchase of the Purchased Shares) by, or enforcement against, such Purchaser of this Agreement or the transactions contemplated hereby.

  • Required Consents No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition: (A) the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (x) an Event of Default has occurred and is continuing at the time of such assignment, or (y) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; provided that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within ten Business Days after having received notice thereof; (B) the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments if such assignment is to a Person that is not a Lender with a Commitment, an Affiliate of such Lender or an Approved Fund; and (C) the consent of each LC Issuing Bank and Swingline Lender shall be required for any assignment.

  • No Conflict; Consents and Approvals (a) The execution, delivery and performance of this Agreement by each of the Parent Parties does not, and the consummation of the Mergers and the other transactions contemplated hereby and compliance by each of the Parent Parties with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Encumbrance in or upon any of the properties, assets or rights of the Parent Parties under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i) the organizational documents of the Parent Parties, (ii) any Contract to which a Parent Party is a party or by which such Parent Party or any of its respective properties or assets may be bound or (iii) subject to the governmental filings and other matters referred to in Section 4.4(b), any material Law or any rule or regulation of NASDAQ applicable to the Parent Parties or by which the Parent Parties or any of their respective properties or assets may be bound, except in the case of clauses (ii) and (iii) for any such conflicts, violations, breaches, defaults, failures to obtain consents or approvals or other occurrences that would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. (b) No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to the Parent Parties in connection with the execution, delivery and performance of this Agreement by the Parent Parties or the consummation by the Parent Parties of the Mergers and the other transactions contemplated hereby or compliance with the provisions hereof, except for (i) the filing of the pre-merger notification report under the HSR Act, (ii) such filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and “blue sky” laws, (iii) the filing of the Certificates of Merger with the Delaware Secretary of State as required by the DGCL or DLLCA, as applicable, (iv) any filings required under the rules and regulations of NASDAQ and (v) such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect.

  • Governmental Authorities; Consents No action by, consent, approval, permit or authorization of, or designation, declaration or filing with, any Governmental Authority or notice, approval, consent waiver or authorization from any Governmental Authority is required on the part of Acquiror with respect to the execution or delivery and performance of this Agreement by Acquiror or any Transaction Agreement to which any of Acquiror is a party, as applicable, or the consummation of the Transactions or the transactions contemplated thereby, except for (a) applicable requirements of the HSR Act, (b) the filing with the SEC of (i) the Proxy Statement (and the expiration of the waiting period in Rule 14a-6(a) under the Exchange Act or, if the preliminary Proxy Statement is reviewed by the SEC, receipt of oral or written notification of the completion of the review by the SEC) and (ii) such reports under Section 13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Transaction Agreements or the Transactions or the transactions contemplated thereby, (c) such filings with and approval of Nasdaq to permit the Acquiror Common Stock to be issued in connection with the Transactions and the other Transaction Agreements to be listed on the Nasdaq, (d) the Acquiror Stockholder Approval, or (e) any actions, consents, approvals, permits or authorizations, designations, declarations or filings, the absence of which would not, individually or in the aggregate, reasonably be expected to have an Acquiror Material Adverse Effect.

  • Approvals; Consents Where agreement, approval, acceptance or consent by either Party is required by any provision of this Agreement such action shall not be unreasonably delayed or withheld.

  • Authorization; Consents The execution, delivery and performance by the Allocatee of the Allocation Agreement and the carrying out of the authorized use(s) of the NMTC Allocation provided hereunder are within the Allocatee’s powers and have been duly authorized by all necessary corporate, partnership or limited liability company action and no consent, approval, authorization or order of, notice to and filing with, any third party including, without limitation, any governmental entity which has not been previously obtained, is required in connection with such execution, delivery and performance. The Allocatee will make all such notices or filings that may be required after the Allocation Date in accordance with the applicable time periods for such notices or filings.

  • No Conflict; Consents Except as set forth in Disclosure Schedule 4.3: (a) the execution, delivery and performance of this Agreement by the Partnership Parties does not, and the execution, delivery and performance by the Partnership Parties of any of the Partnership Ancillary Documents will not, and the fulfillment and compliance with the terms and conditions hereof and thereof and the consummation of the transactions contemplated hereby and thereby will not, (i) violate, conflict with any of, result in any breach of, or require the consent of any Person under, the terms, conditions or provisions of the certificate of limited partnership, certificate of formation, limited liability company agreement, agreement of limited partnership or other equivalent governing instruments of any Partnership Party; (ii) conflict with or violate any provision of any Law applicable to any Partnership Party; (iii) conflict with, result in a breach of, constitute a default under (whether with notice or the lapse of time or both), or accelerate or permit the acceleration of the performance required by, or require any consent, authorization or approval under, or result in the suspension, termination or cancellation of, or in a right of suspension, termination or cancellation of, any indenture, mortgage, agreement, contract, commitment, license, concession, Permit, lease, joint venture or other agreement or instrument to which any of the Partnership Parties is a party or by which either of them is bound or to which any of their property is subject; or (iv) result in the creation of any Lien (other than Permitted Liens) on any of the Partnership Parties’ assets, except in the case of clauses (ii), (iii) or (iv), for those items which, individually or in the aggregate, would not have (or be reasonably expected to have) a Partnership Material Adverse Effect; and (b) no consent, approval, license, Permit, order or authorization of any Governmental Authority or other Person is required to be obtained or made by the Partnership Parties in connection with the execution, delivery, and performance of this Agreement and the Partnership Ancillary Documents or the consummation of the transactions contemplated hereby or thereby, except (i) as have been waived or obtained or with respect to which the time for asserting such right has expired or (ii) for those that individually or in the aggregate, would not have a Partnership Material Adverse Effect (including such consents, approvals, orders or Permits that are not customarily obtained prior to the Closing and are reasonably expected to be obtained in the ordinary course of business consistent with past practices following the Closing).

  • Government Consents Borrower and each Subsidiary have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all governmental authorities that are necessary for the continued operation of Borrower’s business as currently conducted, except where the failure to do so would not reasonably be expected to cause a Material Adverse Effect.

  • Consents in force All the consents referred to in Clause 10.4 remain in force and nothing has occurred which makes any of them liable to revocation.